<DOC>
	<DOC>NCT02797067</DOC>
	<brief_summary>The purpose of the study is to determine whether rectal indomethacin reduces the incidence of post-ESWL pancreatitis.</brief_summary>
	<brief_title>Rectal Indomethacin to Prevent Post ESWL-pancreatitis</brief_title>
	<detailed_description>It is a prospective, double-blind, randomized controlled trial. Patients with painful chronic pancreatitis and pancreatic stones (&gt; 5 mm in diameter) who are treated with ESWL at Changhai Hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Glycerol</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<criteria>any patient with painful chronic pancreatitis and pancreatic stones (&gt; 5 mm in diameter) undergoing PESWL at least 18 years old provides informed consent contraindications to ESWL suspected or established malignancy pancreatic ascites receiving NSAIDs within 7 days contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine &gt;120 Î¼mol/L) presence of coagulopathy or received anticoagulation therapy within 3 days acute pancreatitis within 3 days known active cardiovascular or cerebrovascular disease pregnant or breastfeeding women without a rectum (ie, status posttotal proctocolectomy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Extracorporeal Shock Wave lithotripsy(ESWL)</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Indomethacin</keyword>
	<keyword>Chronic pancreatitis</keyword>
</DOC>